Skip to main content

Safety of intravenous administration of hydrogen-enriched fluid in patients with acute cerebral ischemia: initial clinical studies

Type of Publication
Year of Publication
2013
Authors

K. Nagatani; H. Nawashiro; S. Takeuchi; S. Tomura; N. Otani; H. Osada; K. Wada; H. Katoh; N. Tsuzuki; K. Mori

Abstract

BACKGROUND: Most of the results regarding hydrogen (H2) therapy for acute cerebral ischemia are derived from in vitro studies and animal experiments, with only a few obtained from human trials with a limited number of subjects. Thus, there is a paucity of information regarding both the beneficial therapeutic effects as well as the side effects of H2 on acute cerebral ischemia in humans. We designed a pilot study to investigate single dose intravenous H2-administration in combination with edaravone, aiming to provide an initial estimate of the possible risks and benefits in select patients presenting with acute ischemic stroke. METHODS: An open-label, prospective, non-randomized study of intravenous H2-administration was performed in 38 patients hospitalized for acute ischemic stroke. All patients received an H2-enriched intravenous solution in addition to edaravone immediately after the diagnosis of acute ischemic stroke. Acute stroke patients within 3h of onset received intravenous tissue plasminogen activator (t-PA) (0.6mg/kg) treatment, and patients receiving t-PA had to commence the administration of the H2-enriched intravenous solution and edaravone before or at the same time as the t-PA was infused. RESULTS: Complications were observed in 2 patients (5.3%2, which consisted of diarrhea in 1 patient (2.6%2 and cardiac failure in 1 patient (2.6%2. No deterioration in laboratory tests, urinary tests, ECG, or chest X-ray radiograms occurred in any patient in this study. In all patients, the mean National Institutes of Health Stroke Scale (NIHSS) scores at baseline, and 7, 30, and 90 d after admission were 8.2 7.5, 5.6 7.1, 4.9 6.5, and 4.5 6.3, respectively. The early recanalization was identified in 4 of 11 patients (36.4%2 who received intravenous t-PA administration. Hemorrhagic transformation was observed in 2 patients (18.2%2. None of the patients in this study that were treated with t-PA developed symptomatic intracranial hemorrhage. CONCLUSIONS: Data from the current study indicate that an H2-enriched intravenous solution is safe for patients with acute cerebral infarction, including patients treated with t-PA.

DOI

10.1186/2045-9912-3-13

Volume

3

Notes

4

Pagination

13-13

We are professional and reliable provider since we offer customers the most powerful and beautiful themes. Besides, we always catch the latest technology and adapt to follow world’s new trends to deliver the best themes to the market.

Contact info

We are the leaders in the building industries and factories. We're word wide. We never give up on the challenges.

Recent Posts